

Jan J Stepan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7919114/publications.pdf>

Version: 2024-02-01

173
papers

13,017
citations

36203

51
h-index

22764

112
g-index

185
all docs

185
docs citations

185
times ranked

9490
citing authors

#	ARTICLE	IF	CITATIONS
1	A decrease in serum 1,25(OH) ₂ D after elective hip replacement and during bone healing is associated with changes in serum iron and plasma FGF23. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 1039-1044.	1.8	2
2	Menopausal Transition: Prospective Study of Estrogen Status, Circulating MicroRNAs, and Biomarkers of Bone Metabolism. <i>Frontiers in Endocrinology</i> , 2022, 13, .	1.5	6
3	Treatment of postmenopausal osteoporosis patients with teriparatide for 24 months reverts forming bone quality indices to premenopausal healthy control values. <i>Bone</i> , 2022, 162, 116478.	1.4	4
4	Decrease in serum calcitriol (but not free 25-hydroxyvitamin D) concentration in hip fracture healing. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1847-1855.	1.8	2
5	Efficacy of teriparatide compared with risedronate on FRAX [®] -defined major osteoporotic fractures: results of the VERO clinical trial. <i>Osteoporosis International</i> , 2020, 31, 1935-1942.	1.3	12
6	S100A4 is elevated in axial spondyloarthritis: a potential link to disease severity. <i>BMC Rheumatology</i> , 2020, 4, 13.	0.6	1
7	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 899-911.	5.5	111
8	Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial. <i>Archives of Osteoporosis</i> , 2019, 14, 10.	1.0	7
9	Update on Menopausal Hormone Therapy for Fracture Prevention. <i>Current Osteoporosis Reports</i> , 2019, 17, 465-473.	1.5	33
10	Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. <i>European Journal of Endocrinology</i> , 2019, 180, P23-P54.	1.9	443
11	Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 783-794.	3.1	84
12	Teriparatide Treatment Increases Mineral Content and Volume in Cortical and Trabecular Bone of Iliac Crest: A Comparison of Infrared Imaging With X-Ray [®] -Based Bone Assessment Techniques. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 2230-2235.	3.1	10
13	Osteoporosis and quality of bone. <i>Vnitřní Lekarství</i> , 2018, 64, 197-208.	0.1	0
14	Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture: Final Results of a 78-Week Randomized Clinical Trial. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1040-1051.	3.1	32
15	Secondary fracture prevention in hip fracture patients requires cooperation from general practitioners. <i>Archives of Osteoporosis</i> , 2017, 12, 49.	1.0	9
16	Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality. <i>Bone</i> , 2017, 95, 41-46.	1.4	47
17	Focal osteoporosis defects play a key role in hip fracture. <i>Bone</i> , 2017, 94, 124-134.	1.4	68
18	How General Practitioners and Their Patients Adhere to Osteoporosis Management: A Follow-Up Survey among Czech General Practitioners. <i>Frontiers in Pharmacology</i> , 2017, 8, 258.	1.6	5

#	ARTICLE	IF	CITATIONS
19	Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment. <i>Bone</i> , 2016, 89, 16-24.	1.4	20
20	Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture. <i>Journal of Bone and Joint Surgery - Series A</i> , 2016, 98, 1868-1878.	1.4	42
21	Serum and bone pentosidine in patients with low impact hip fractures and in patients with advanced osteoarthritis. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 308.	0.8	19
22	Teriparatide for osteoporosis: importance of the full course. <i>Osteoporosis International</i> , 2016, 27, 2395-2410.	1.3	135
23	Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter. <i>Climacteric</i> , 2015, 18, 608-616.	1.1	16
24	Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, 460.	1.6	11
25	Adherence to osteoporosis guideline: survey among Czech general practitioners. <i>Open Medicine (Poland)</i> , 2014, 9, 687-693.	0.6	1
26	Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy. <i>Osteoporosis International</i> , 2014, 25, 2709-2719.	1.3	21
27	The association between lean mass and bone mineral content in the high disease activity group of adult patients with juvenile idiopathic arthritis. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 51.	0.8	16
28	Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. <i>Bone</i> , 2014, 59, 139-147.	1.4	69
29	Acute Effects of Glucocorticoids on Serum Markers of Osteoclasts, Osteoblasts, and Osteocytes. <i>Calcified Tissue International</i> , 2013, 92, 354-361.	1.5	68
30	Bone status in adults with early-onset juvenile idiopathic arthritis following 1-year anti-TNF α therapy and discontinuation of glucocorticoids. <i>Rheumatology International</i> , 2013, 33, 2001-2007.	1.5	10
31	Strontium ranelate: in search for the mechanism of action. <i>Journal of Bone and Mineral Metabolism</i> , 2013, 31, 606-612.	1.3	38
32	Low-dose estrogen combined oral contraceptives may negatively influence physiological bone mineral density acquisition during adolescence. <i>European Journal of Endocrinology</i> , 2012, 166, 1003-1011.	1.9	49
33	A comparison of the acute effects of calcium and strontium ranelate on the serum marker of bone resorption. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 333-5.	1.4	2
34	Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis. <i>Osteoporosis International</i> , 2012, 23, 2885-2891.	1.3	38
35	A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. <i>Osteoporosis International</i> , 2012, 23, 2257-2276.	1.3	291
36	Osteoporosis in young adults: pathophysiology, diagnosis, and management. <i>Osteoporosis International</i> , 2012, 23, 2735-2748.	1.3	188

#	ARTICLE	IF	CITATIONS
37	An appendix to the 2012 IOFâ€™ECTS guidelines for the management of glucocorticoid-induced osteoporosis. Archives of Osteoporosis, 2012, 7, 25-30.	1.0	35
38	Cortical Thickness Mapping to Identify Focal Osteoporosis in Patients with Hip Fracture. PLoS ONE, 2012, 7, e38466.	1.1	110
39	Secondary Osteoporosis: Endocrine and Metabolic Causes of Bone Mass Deterioration. Journal of Osteoporosis, 2012, 2012, 1-2.	0.1	10
40	Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. Journal of Bone and Mineral Research, 2012, 27, 2039-2046.	3.1	330
41	Hip Fracture Incidence from 1981 to 2009 in the Czech Republic as a Basis of the Country-Specific FRAX Model. Calcified Tissue International, 2012, 90, 365-372.	1.5	19
42	Official Positions for FRAX® Clinical Regarding Biochemical Markers. Journal of Clinical Densitometry, 2011, 14, 220-222.	0.5	41
43	Official Positions for FRAX® Clinical Regarding Falls and Frailty: Can Falls and Frailty be Used in FRAX®?. Journal of Clinical Densitometry, 2011, 14, 194-204.	0.5	107
44	Official Positions for FRAX® Clinical Regarding Smoking. Journal of Clinical Densitometry, 2011, 14, 190-193.	0.5	16
45	Official Positions for FRAX® Clinical Regarding Prior Fractures. Journal of Clinical Densitometry, 2011, 14, 205-211.	0.5	23
46	Official Positions for FRAX® Clinical Regarding Rheumatoid Arthritis. Journal of Clinical Densitometry, 2011, 14, 184-189.	0.5	42
47	FRAX® International Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. Journal of Clinical Densitometry, 2011, 14, 237-239.	0.5	19
48	Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. Journal of Clinical Densitometry, 2011, 14, 171-180.	0.5	82
49	Official Positions for FRAX® Clinical Regarding International Differences. Journal of Clinical Densitometry, 2011, 14, 240-262.	0.5	84
50	Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture. Journal of Clinical Densitometry, 2011, 14, 212-219.	0.5	85
51	FRAX® Clinical Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. Journal of Clinical Densitometry, 2011, 14, 181-183.	0.5	11
52	Official Positions for FRAX® Bone Mineral Density and FRAX® Simplification. Journal of Clinical Densitometry, 2011, 14, 226-236.	0.5	45
53	FRAX® Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. Journal of Clinical Densitometry, 2011, 14, 223-225.	0.5	19
54	Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis. Bone, 2011, 48, 972-978.	1.4	26

#	ARTICLE	IF	CITATIONS
55	The effect of timing of teriparatide treatment on the circadian rhythm of bone turnover in postmenopausal osteoporosis. <i>European Journal of Endocrinology</i> , 2011, 164, 643-648.	1.9	35
56	Validation of the IOF quality of life questionnaire for patients with wrist fracture. <i>Osteoporosis International</i> , 2010, 21, 61-70.	1.3	20
57	The effects of strontium ranelate on biochemical markers of bone turnover and their relationship with bone mineral density. <i>Osteoporosis International</i> , 2010, 21, 1037-1038.	1.3	3
58	Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. <i>Osteoporosis International</i> , 2010, 21, 2027-2036.	1.3	55
59	Osteoporosis risk assessment and management in primary care: focus on quantity and quality. <i>Journal of Evaluation in Clinical Practice</i> , 2010, 16, 1176-1182.	0.9	9
60	Comparative Effects of Teriparatide and Strontium Ranelate on Bone Biopsies and Biochemical Markers of Bone Turnover in Postmenopausal Women With Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1358-1368.	3.1	103
61	Teriparatide Reduces Bone Microdamage Accumulation in Postmenopausal Women Previously Treated With Alendronate. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1998-2006.	3.1	69
62	Response to Comparison of Teriparatide and Strontium Ranelate in Postmenopausal Women With Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 2067-2068.	3.1	1
63	Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone. <i>Bone</i> , 2009, 44, 634-638.	1.4	7
64	Changes of bone turnover markers after 6 months of treatment with either morning or evening teriparatide administration in women with severe postmenopausal osteoporosis. <i>Bone</i> , 2009, 44, S427-S428.	1.4	1
65	BMD and biochemical markers of bone turnover in adolescent girls on oral contraceptives with different estrogen content. <i>Bone</i> , 2009, 44, S259.	1.4	0
66	Geographical variation in DXA bone mineral density in young European men and women. Results from the Network in Europe on male osteoporosis (NEMO) study. <i>Bone</i> , 2008, 43, 332-339.	1.4	39
67	Marker of Bone Resorption in Acute Response to Exogenous or Endogenous Parathyroid Hormone. <i>Biomarker Insights</i> , 2008, 3, 117727190800300.	1.0	8
68	Marker of Bone Resorption in Acute Response to Exogenous or Endogenous Parathyroid Hormone. <i>Biomarker Insights</i> , 2008, 3, 19-24.	1.0	6
69	Geographic and other determinants of BMD change in European men and women at the hip and spine. A population-based study from the Network in Europe for Male Osteoporosis (NEMO). <i>Bone</i> , 2007, 40, 662-673.	1.4	27
70	Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. <i>Bone</i> , 2007, 41, 378-385.	1.4	141
71	The Association between Common Vitamin D Receptor Gene Variations and Osteoporosis: A Participant-Level Meta-Analysis. <i>Annals of Internal Medicine</i> , 2006, 145, 255.	2.0	219
72	Whom to treat? The contribution of vertebral X-rays to risk-based algorithms for fracture prediction. Results from the European Prospective Osteoporosis Study. <i>Osteoporosis International</i> , 2006, 17, 1369-1381.	1.3	34

#	ARTICLE	IF	CITATIONS
73	Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 654-661.	0.5	278
74	The Effect of Raloxifene after Discontinuation of Long-Term Alendronate Treatment of Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 870-877.	1.8	37
75	Clinical value of the biochemical markers of bone remodeling in the assessment of bone metabolic diseases. <i>Journal of Medical Biochemistry</i> , 2006, 25, 241-248.	0.1	2
76	The Risk of Collesâ€™ Fracture is Associated with the Collagen I Alpha1 Sp1 Polymorphism and Ultrasound Transmission Velocity in the Calcaneus Only in Heavier Postmenopausal Women. <i>Calcified Tissue International</i> , 2005, 76, 98-106.	1.5	9
77	Low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study. <i>Bone</i> , 2005, 36, 387-398.	1.4	88
78	Sustained Vertebral Fracture Risk Reduction After Withdrawal of Teriparatide in Postmenopausal Women With Osteoporosis. <i>Archives of Internal Medicine</i> , 2004, 164, 2024.	4.3	275
79	Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1751-1761.	3.0	680
80	Adipokine levels in Cushing's syndrome; elevated resistin levels in female patients with Cushing's syndrome. <i>Clinical Endocrinology</i> , 2004, 60, 350-357.	1.2	43
81	The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance. <i>Clinical Endocrinology</i> , 2004, 60, 442-450.	1.2	58
82	Health-related quality of life and radiographic vertebral fracture. <i>Osteoporosis International</i> , 2004, 15, 113-119.	1.3	161
83	Back pain, disability, and radiographic vertebral fracture in European women: a prospective study. <i>Osteoporosis International</i> , 2004, 15, 760-765.	1.3	106
84	Diminished Acute Response of Osteoclasts to Calcium Load in Thyroidectomized Patients. <i>Calcified Tissue International</i> , 2004, 74, 377-381.	1.5	1
85	Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids. <i>Clinica Chimica Acta</i> , 2004, 348, 147-154.	0.5	22
86	Determinants of the Size of Incident Vertebral Deformities in European Men and Women in the Sixth to Ninth Decades of Age: The European Prospective Osteoporosis Study (EPOS). <i>Journal of Bone and Mineral Research</i> , 2003, 18, 1664-1673.	3.1	33
87	Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). <i>Osteoporosis International</i> , 2003, 14, 19-26.	1.3	251
88	Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. <i>Osteoporosis International</i> , 2003, 14, 741-749.	1.3	29
89	Clinical utility of bone markers in the evaluation and follow-up of osteoporotic patients: Why are the markers poorly accepted by clinicians?. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 458-463.	1.8	9
90	Calcitonin load test to assess the efficacy of salmon calcitonin. <i>Clinica Chimica Acta</i> , 2003, 336, 49-55.	0.5	1

#	ARTICLE	IF	CITATIONS
91	The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: the influence of vitamin D deficiency and hormonal status. <i>Bone</i> , 2003, 33, 589-596.	1.4	44
92	Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS). <i>Bone</i> , 2003, 33, 505-513.	1.4	192
93	Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 969-975.	0.5	66
94	Plasma type 1 collagen cross-linked C-telopeptide: a sensitive marker of acute effects of salmon calcitonin on bone resorption. <i>Clinica Chimica Acta</i> , 2002, 316, 63-69.	0.5	17
95	Is the predictive power of previous fractures for new spine and non-spine fractures associated with biochemical evidence of altered bone remodelling? The EPOS study. <i>Clinica Chimica Acta</i> , 2002, 322, 121-132.	0.5	8
96	Falls explain between-center differences in the incidence of limb fracture across Europe. <i>Bone</i> , 2002, 31, 712-717.	1.4	47
97	Techniques for measuring bone mineral density. <i>International Congress Series</i> , 2002, 1229, 63-68.	0.2	5
98	Improving Risk Assessment: Hip Geometry, Bone Mineral Distribution and Bone Strength in Hip Fracture Cases and Controls. The EPOS Study. <i>Osteoporosis International</i> , 2002, 13, 48-54.	1.3	122
99	Incidence of Limb Fracture across Europe: Results from the European Prospective Osteoporosis Study (EPOS). <i>Osteoporosis International</i> , 2002, 13, 565-571.	1.3	191
100	Defining Incident Vertebral Deformities in Population Studies: A Comparison of Morphometric Criteria. <i>Osteoporosis International</i> , 2002, 13, 809-815.	1.3	42
101	Incidence of Vertebral Fracture in Europe: Results From the European Prospective Osteoporosis Study (EPOS). <i>Journal of Bone and Mineral Research</i> , 2002, 17, 716-724.	3.1	551
102	Prevalent Vertebral Deformity Predicts Incident Hip though not distal Forearm Fracture: Results from the European Prospective Osteoporosis Study. <i>Osteoporosis International</i> , 2001, 12, 85-90.	1.3	159
103	Acute Effects in Healthy Women of Oral Calcium on the Calcium-Parathyroid Axis and Bone Resorption as Assessed by Serum b-CrossLaps. <i>Calcified Tissue International</i> , 2001, 68, 352-357.	1.5	32
104	Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial. <i>Breast Cancer Research and Treatment</i> , 2001, 65, 125-134.	1.1	629
105	Increase of adhesion molecules, fibrinogen, type-1 plasminogen activator inhibitor and orosomucoid in growth hormone (GH) deficient adults and their modulation by recombinant human GH replacement. <i>Clinical Endocrinology</i> , 2000, 52, 543-548.	1.2	49
106	The Use of Biochemical Markers of Bone Turnover in Osteoporosis. <i>Osteoporosis International</i> , 2000, 11, S2-S17.	1.3	604
107	Prediction of Bone Loss in Postmenopausal Women. <i>Osteoporosis International</i> , 2000, 11, S45-S54.	1.3	57
108	Hip geometry, bone mineral distribution, and bone strength in European men and women: the EPOS study. <i>Bone</i> , 2000, 27, 151-159.	1.4	94

#	ARTICLE	IF	CITATIONS
109	COLIA1 polymorphism contributes to bone mineral density to assess prevalent wrist fractures. <i>Bone</i> , 2000, 26, 287-290.	1.4	71
110	Two-Site Immunoassays for Osteoclastic Tartrate-Resistant Acid Phosphatase Based on Characterization of Six Monoclonal Antibodies. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 464-469.	3.1	42
111	Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study. <i>Osteoporosis International</i> , 1999, 9, 461-468.	1.3	521
112	Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis. <i>Clinica Chimica Acta</i> , 1999, 288, 121-135.	0.5	27
113	ApoE genotype is not associated with variations in bone mineral density. <i>Atherosclerosis</i> , 1999, 144, 103-104.	0.4	8
114	Bone mineral density in patients with phenylketonuria. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1999, 88, 1348-51.	0.7	24
115	Body composition in children receiving recombinant human growth hormone after renal transplantation. <i>Kidney International</i> , 1998, 54, 951-955.	2.6	10
116	Beta 2-microglobulin does not behave as a biological marker of bone remodelling in patients with primary hyperparathyroidism. <i>Clinica Chimica Acta</i> , 1998, 278, 61-66.	0.5	0
117	Spinal Bone Mineral Density in Children with Celiac Disease. <i>Journal of Clinical Densitometry</i> , 1998, 1, 129-136.	0.5	12
118	Studies on the Protein Tyrosine Phosphatase Activity of Tartrate-Resistant Acid Phosphatase. <i>Archives of Biochemistry and Biophysics</i> , 1998, 352, 97-102.	1.4	48
119	Immunocytochemical detection of estrogen receptors in bone cells using flow cytometry. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1997, 1356, 95-100.	1.9	7
120	Letter. <i>Osteoporosis International</i> , 1996, 6, 183-184.	1.3	2
121	TRANSIENT HYPERPHOSPHATASAEMIA AND MALABSORPTION SYNDROME. <i>Journal of Paediatrics and Child Health</i> , 1996, 32, 197-197.	0.4	2
122	Transient hyperphosphatasaemia in infancy associated with an increased urinary hydroxyproline excretion. <i>Clinica Chimica Acta</i> , 1995, 233, 115-118.	0.5	13
123	Galactosyl hydroxylysine in assessment of Paget's bone disease. <i>Clinica Chimica Acta</i> , 1995, 234, 101-108.	0.5	9
124	Anabolic effects of progestogens in bone remodelling. <i>Sborník lékařské společnosti ČKA, 1995, 96, 293-7.</i>	0.2	0
125	Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. <i>Osteoporosis International</i> , 1994, 4, 368-381.	1.3	1,856
126	Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment. <i>Bone and Mineral</i> , 1992, 17, 377-388.	2.0	70

#	ARTICLE	IF	CITATIONS
127	Quantitation of growth factors in ossein-mineral-compound. <i>Life Sciences</i> , 1991, 49, PL79-PL84.	2.0	4
128	Evidence that tartrate-resistant acid phosphatases from osteoclastomas and hairy cell leukemia spleen are members of a multigene family. <i>International Journal of Biochemistry & Cell Biology</i> , 1991, 23, 1237-1244.	0.8	12
129	Prospektive Untersuchung der Osteoporose-prophylaktischen Wirkung von Ossein-Mineral-Komplex bei Patientinnen mit artefizieller Postmenopause. , 1991, , 513-515.		0
130	Development of an Immunoassay for Human Serum Osteoclastic Tartrate-Resistant Acid Phosphatase*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 71, 442-451.	1.8	103
131	Purification and N-terminal amino acid sequence of the tartrate-resistant acid phosphatase from human osteoclastoma: Evidence for a single structure. <i>Biochemical and Biophysical Research Communications</i> , 1990, 168, 792-800.	1.0	17
132	Castrated Men Exhibit Bone Loss: Effect of Calcitonin Treatment on Biochemical Indices of Bone Remodeling*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1989, 69, 523-527.	1.8	425
133	The application of plasma tartrate-resistant acid phosphatase to assess changes in bone resorption in response to artificial menopause and its treatment with estrogen or norethisterone. <i>Calcified Tissue International</i> , 1989, 45, 273-280.	1.5	42
134	Purification and N-terminal sequence of two tartrate-resistant acid phosphatases type-5 from the hairy cell leukemia spleen. <i>Biochemical and Biophysical Research Communications</i> , 1989, 165, 1027-1034.	1.0	20
135	Prospective trial of ossein-hydroxyapatite compound in surgically induced postmenopausal women. <i>Bone</i> , 1989, 10, 179-185.	1.4	20
136	Bone demineralization, biochemical indices of bone remodeling, and estrogen replacement therapy in adults with turner's syndrome. <i>Journal of Bone and Mineral Research</i> , 1989, 4, 193-198.	3.1	64
137	Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastases, and patients with primary hyperparathyroidism. <i>Neoplasma</i> , 1989, 36, 495-501.	0.7	7
138	Serum Osteocalcin Levels and Bone Alkaline Phosphatase Isoenzyme after Oophorectomy and in Primary Hyperparathyroidism*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1987, 64, 1079-1082.	1.8	65
139	Primary hyperparathyroidism and hyperuricaemia are associated but not correlated with indicators of bone turnover. <i>Clinica Chimica Acta</i> , 1987, 170, 195-200.	0.5	20
140	Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. <i>Bone</i> , 1987, 8, 279-284.	1.4	264
141	Serum osteocalcin, bone alkaline phosphatase isoenzyme and plasma tartrate resistant acid phosphatase in patients on chronic maintenance hemodialysis. <i>Bone and Mineral</i> , 1987, 3, 177-83.	2.0	19
142	Role of Secondary Hyperparathyroidism and Liver Function in Hyperamylasemia in Chronic Renal Failure. <i>Digestion</i> , 1986, 33, 168-175.	1.2	3
143	Correlation between Mass of Parathyroid Adenoma and Biochemical Indicators of Bone Turnover in Patients with Primary Hyperparathyroidism. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1986, 88, 360-364.	0.6	2
144	Age and sex dependency of the biochemical indices of bone remodelling. <i>Clinica Chimica Acta</i> , 1985, 151, 273-283.	0.5	55

#	ARTICLE	IF	CITATIONS
145	The Activity of the Bone Isoenzyme of Serum Alkaline Phosphatase and Urinary Hydroxyproline Excretion in Premenopausal and Postmenopausal Women with Primary Hyperparathyroidism. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1984, 83, 315-319.	0.6	0
146	Metabolic implications in the elevation of serum activity of intestinal alkaline phosphatase in chronic renal failure. <i>Experientia</i> , 1984, 40, 896-898.	1.2	3
147	Biochemical assessment of bone disease in multiple myeloma. <i>Clinica Chimica Acta</i> , 1984, 142, 203-209.	0.5	9
148	Alterations in human serum alkaline phosphatase and its bone isoenzyme by chronic administration of lithium. <i>Clinica Chimica Acta</i> , 1984, 140, 151-155.	0.5	6
149	Serum lipase, isoamylase and pancreatic function test (PFT) in juvenile-onset insulin-dependent diabetes mellitus. <i>Acta Diabetologica Latina</i> , 1983, 20, 357-361.	0.2	6
150	Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. <i>Clinica Chimica Acta</i> , 1983, 133, 189-200.	0.5	99
151	Plasma 25-Hydroxycholecalciferol in Oral Sulfonylurea Treated Diabetes Mellitus. <i>Hormone and Metabolic Research</i> , 1982, 14, 98-100.	0.7	12
152	Serum and urinary amylase isoenzymes in carcinoma of the prostate. <i>Clinica Chimica Acta</i> , 1982, 121, 11-14.	0.5	2
153	Crossed digoxin immunoreactivity in chromatographic fractions of rat adrenal extract. <i>Biochemical Pharmacology</i> , 1981, 30, 805-806.	2.0	15
154	Digitalis glycoside-like biological activity (inhibition of $^{86}\text{Rb}^+$ uptake by red blood cells in vitro) of certain steroids and other hormones. <i>Biochemical Pharmacology</i> , 1981, 30, 3001-3002.	2.0	7
155	Digoxin-like immunoreactivity in the serum of rats with cardiac overload. <i>Journal of Molecular and Cellular Cardiology</i> , 1981, 13, 107-110.	0.9	55
156	Isoamylases in diabetes mellitus. <i>Diabetologia</i> , 1981, 20, 129-133.	2.9	10
157	Amylase isoenzymes in mumps. <i>European Journal of Pediatrics</i> , 1979, 132, 99-105.	1.3	3
158	Bone isoenzyme of serum alkaline phosphatase in acromegaly. <i>Clinica Chimica Acta</i> , 1979, 93, 355-363.	0.5	21
159	A modified inactivation - inhibition method for determining the serum activity of alkaline phosphatase isoenzymes. <i>Clinica Chimica Acta</i> , 1976, 69, 1-9.	0.5	56
160	Phosphatases, X. Study on the Mechanism of Induction of Alkaline Phosphatase Activity in Rat Liver after Bile Flow Obstruction. Purification of the Inducible Liver Alkaline Phosphatase and Incorporation of Radioactive Precursors. <i>Hoppe-Seyler's Zeitschrift für Physiologische Chemie</i> , 1973, 354, 1462-1472.	1.7	15
161	Phosphatases VI.1 pH dependence of the organ-specific thermostability of alkaline phosphatases in tissue homogenates. <i>Experientia</i> , 1972, 28, 1284-1285.	1.2	4
162	Some enzyme and isoenzyme activities in <i>Trichomonas vaginalis</i> . <i>Folia Microbiologica</i> , 1971, 16, 142-143.	1.1	4

#	ARTICLE	IF	CITATIONS
163	Isoenzyme of some dehydrogenases and nonspecific esterase in experimental virus hepatitis in mice. <i>Experientia</i> , 1970, 26, 1397-1398.	1.2	0
164	Additional electrophoretic differentiation of LDH5 and mitochondrial GOT in ionic strength and pH gradients. <i>FEBS Letters</i> , 1969, 4, 151-154.	1.3	1
165	Alkaline phosphatase, lactate dehydrogenase and aspartate aminotransferase and their isoenzymes as indicators of the development of experimental virus hepatitis in mice. <i>Clinica Chimica Acta</i> , 1969, 26, 497-504.	0.5	5
166	Phosphatasen, IV. Die Trennung der Isoenzyme der alkalischen Phosphatase aus Rattenserum (normal) Tj ETQq0 0 0 rgBT /Overlock 10 T Agar- und Agarosesorten. <i>Hoppe-Seyler's Zeitschrift für Physiologische Chemie</i> , 1967, 348, 1307-1310.	1.7	0
167	Phosphatasen, V. Intrazelluläre Verteilung der Isoenzyme der alkalischen Phosphatase der Rattenleber und ihr Verhalten nach Unterbindung des Ductus choledochus. <i>Hoppe-Seyler's Zeitschrift für Physiologische Chemie</i> , 1967, 348, 1311-1318.	1.7	17
168	A new method of detection of inorganic phosphate on paper. <i>Journal of Chromatography A</i> , 1966, 24, 298-299.	1.8	3
169	Acute effects of glucocorticoids on CRP and bone markers. <i>Bone Abstracts</i> , 0, , .	0.0	0
170	Glucocorticoids aggravate reduction in mineral and lean mass in active juvenile idiopathic arthritis. <i>Bone Abstracts</i> , 0, , .	0.0	0
171	Impact of 3-year vitamin D and calcium supplementation on mineral and organic matrix formation of trabecular bone in postmenopausal osteoporosis. <i>Bone Abstracts</i> , 0, , .	0.0	0
172	Impact of 3-year vitamin D and calcium supplementation on mineral and organic matrix formation of trabecular bone in postmenopausal osteoporosis. <i>Bone Abstracts</i> , 0, , .	0.0	0
173	Focal osteoporosis associated with hip fracture involves both trabecular and cortical bone; a 3D cortical bone mapping study of cases and controls using clinical CT. <i>Bone Abstracts</i> , 0, , .	0.0	0